FORT LAUDERDALE, Fla., Nov. 11 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc. (BULLETIN BOARD: IMDS) announced today that the Comprehensive Cancer Centre in Gliwice, Poland, has signed a clinical collaborative agreement to gather data to expand diagnostic and therapeutic applications of the CT Laser Mammography (CTLM)(R) system.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO)
"Management of the Institute is proud to have been selected as a 'Center of Excellence' for this innovative breakthrough technology in Central Europe. This new device well complements our plans of improving the capabilities of the Breast Imaging and Treatment Center. The CTLM will monitor various stages of the angiogenesis reduction in the area of the cancerous mass during therapy. Adding our clinical expertise and our scientific program in Molecular and Functional Imaging will definitely accelerate the CTLM role in breast cancer diagnosis and treatment," stated Professor Maciejewski, M.D. Ph.D., Director and Head of Radiotherapy department of the Comprehensive Cancer Centre (http://www.io.gliwice.pl/).
Deborah O'Brien, IDSI Senior Vice President, added, "We are very pleased to have signed this collaborative agreement. Professor Maciejewski will join our effort with the full support of a Centre registered by the 'Organization of European Cancer Institutes' as a European Comprehensive Centre of Excellence. This relationship should lead to faster availability of CTLM to the female populations in the region."
The CTLM(R) system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, UL listing, ISO 9001:2000-13488 certification, China SFDA and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking Pre-Market Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM(R) system to be used as an adjunct to mammography.
Please visit Imaging Diagnostic Systems' website at: http://www.imds.com/ for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filing with the Securities Exchange Commission.
Investor Relations: Rick Lutz 404-261-1196 lcgroup@mindspring.com Company Contact: Deborah O'Brien 954-581-9800 obrien@imds.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comImaging Diagnostic SystemsCONTACT: Deborah O'Brien, Imaging Diagnostic Systems, +1-954-581-9800,or obrien@imds.com; or investors, Rick Lutz, +1-404-261-1196, orlcgroup@mindspring.com, for Imaging Diagnostic Systems